Results from the Phase III Randomized Trial of Onartuzumab plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung

1. Spigel, D.R.
2. Edelman, M.J.
3. O’Byrne, K.
4. Paz-Ares, L.
5. Mocci, S.
6. Phan, S.
7. Shames, D.S.
8. Smith, D.
9. Yu, W.
10. Paton, V.E.
11. Mok, T.